Announced Date: 2025-05-29 (May 29, 2025) Asset Name: XNW27011 Licensor: Evopoint (Evopoint Biosciences Co., Ltd., China) Licensee … [China BD 2025] Evopoint and Astellas enters a 1.54 billion USD license on CLDN18.2 ADC XNW27011Read more
Author: admin
[China FIC Drug] Influenza A virus RNA Polymerase PB2 Inhibitor First in Class Drug Onradivir Approved by China NMPA in 2025
Drug Name: Onradivir Drug Modality: Small Molecule Drug Target: Influenza A virus RNA Polymerase PB2 Inhibitor Developed By：Guangdong Raynovent Biotech … [China FIC Drug] Influenza A virus RNA Polymerase PB2 Inhibitor First in Class Drug Onradivir Approved by China NMPA in 2025Read more
[China BD 2025] Qyuns and Caldera Entered a License for Bispecific Antibody QX030N
Announced Date: 2025-04-23 (April 23, 2025) Asset Name: QX030N Licensor (Seller): Qyuns Therapeutics (China) Licensee (Buyer): … [China BD 2025] Qyuns and Caldera Entered a License for Bispecific Antibody QX030NRead more
[China BD 2025] VelaVigo and Ollin Biosciences Enters a 440 million USD License on IGF-1R/TSHR BsAbs VBS-102
Announced Date: 2025-04-18 (April 18, 2025) Asset Name: VBS-102 Licensor: VelaVigo Bio (China) Licensee (Buyer): Ollin … [China BD 2025] VelaVigo and Ollin Biosciences Enters a 440 million USD License on IGF-1R/TSHR BsAbs VBS-102Read more
[China BD 2025] Puhe BioPharma and AstraZeneca enters a 2 billion USD license on PRMT5i PH020 (BAY 3713372)
Announced Date: 2025-03-26 (March 26, 2025) Asset Name: PH020 (BAY 3713372) Licensor: Suzhou Puhe BioPharma (China) Licensee … [China BD 2025] Puhe BioPharma and AstraZeneca enters a 2 billion USD license on PRMT5i PH020 (BAY 3713372)Read more
[China BD 2025] Hengrui and MSD enters a 2 billion USD license for oral Lpa inhibitor HRS-5346
Announced Date: 2025-03-25 (March 25, 2025) Asset Name: HRS-5346 Licensor: Hengrui Pharma (Jiangsu Hengrui Pharmaceuticals Co., … [China BD 2025] Hengrui and MSD enters a 2 billion USD license for oral Lpa inhibitor HRS-5346Read more
[China BD Deal] TUL and Novo Nordisk enters a 2 billion USD license for UBT251, a GLP-1/GIP/glucagon triple receptor agonist
Announced Date: 2025-03-24 (March 24, 2025) Asset Name: UBT251 Licensor: United Laboratories (The United Laboratories International … [China BD Deal] TUL and Novo Nordisk enters a 2 billion USD license for UBT251, a GLP-1/GIP/glucagon triple receptor agonistRead more
[Technology Collaboration] Syneron Bio and AstraZeneca enters a 3.5 billion USD Collaboration on oral macrocyclic peptide drug research
Announced Date: 2025-03-21 (March 21, 2025) Licensor: Syneron Bio (China) Licensee: AstraZeneca（UK） Collaboration Object: Co-develop potential … [Technology Collaboration] Syneron Bio and AstraZeneca enters a 3.5 billion USD Collaboration on oral macrocyclic peptide drug researchRead more
[China BD 2025] CSPC and Radiance enters a 1.24 billion USD license on ROR1 ADC SYS6005 (RB-164)
Announced Date: 2025-02-19 (February 19, 2025) Asset Name: SYS6005 (RB-164) Licensor: CSPC Pharmaceutical Group (China) together … [China BD 2025] CSPC and Radiance enters a 1.24 billion USD license on ROR1 ADC SYS6005 (RB-164)Read more
[China BD 2025] Lepu Biopharma and ArriVent enters a 1.2 billion USD License on CDH17 ADC MRG007
Announced Date: 2025-01-22 (January 22, 2025) Licensor (Seller): Lepu Biopharma (China) Licensee (Buyer): ArriVent BioPharma (US) … [China BD 2025] Lepu Biopharma and ArriVent enters a 1.2 billion USD License on CDH17 ADC MRG007Read more